Literature DB >> 11448020

Identification of a novel frameshift mutation (383insT) in the RUNX2 (PEBP2 alpha/CBFA1/AML3) gene in a Japanese patient with cleidocranial dysplasia.

M Goseki-Sone1, H Orimo, A Watanabe, R Hamatani, M Yokozeki, K Ohyama, T Kuroda, H Watanabe, H Miyazaki, T Shimada, S Oida.   

Abstract

Cleidocranial dysplasia (CCD) is an autosomal dominant disorder due to mutations in runt-related gene 2 (RUNX2)/polyomavirus enhancer-binding protein 2alphaA (PEBP2alphaA)/core-binding factor A1 (CBFA1)/acute myeloid leukemia 3 (AML3). To investigate the RUNX2 mutations in a Japanese patient with classic CCD, we analyzed the RUNX2 gene using polymerase chain reaction (PCR)-single-strand conformation polymorphism and PCR-restriction fragment length polymorphism. The patient had hypoplasia of the clavicles, patent fontanelles, short stature, supernumerary teeth, and retention of deciduous dentition. We identified a 1-bp insertion (383insT) at codon 128 of the RUNX2 gene. The 383T insertion affects the conserved residue in the runt domain and results in premature termination in the runt domain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448020     DOI: 10.1007/s007740170030

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  3 in total

1.  [Anomalies of the skull in cleidocranial dysplasia].

Authors:  I Golan; A Waldeck; U Baumert; J Strutz; D Müssig
Journal:  HNO       Date:  2004-12       Impact factor: 1.284

2.  Cooperative binding of DNA and CBFbeta to the Runt domain of the CBFalpha studied via MD simulations.

Authors:  Bahru Habtemariam; Victor M Anisimov; Alexander D MacKerell
Journal:  Nucleic Acids Res       Date:  2005-07-26       Impact factor: 16.971

3.  TET enzymes regulate skeletal development through increasing chromatin accessibility of RUNX2 target genes.

Authors:  Lijun Wang; Xiuling You; Dengfeng Ruan; Rui Shao; Hai-Qiang Dai; Weiliang Shen; Guo-Liang Xu; Wanlu Liu; Weiguo Zou
Journal:  Nat Commun       Date:  2022-08-11       Impact factor: 17.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.